Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Expands By 10,237.3%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 802,797 shares, an increase of 10,237.3% from the June 30th total of 7,766 shares. Based on an average trading volume of 544,670 shares, the short-interest ratio is currently 1.5 days. Currently, 0.2% of the shares of the stock are short sold.

Provectus Biopharmaceuticals Stock Down 0.5%

OTCMKTS PVCT traded down $0.00 during trading on Friday, hitting $0.06. 124,117 shares of the company’s stock were exchanged, compared to its average volume of 253,887. Provectus Biopharmaceuticals has a fifty-two week low of $0.04 and a fifty-two week high of $0.10. The stock’s 50 day moving average price is $0.07 and its two-hundred day moving average price is $0.06.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.